Inclusion Criteria:  The inclusion criteria are confirmed diagnosis of RRMS according to McDonald's diagnostic criteria, age 18-55 inclusive, extended disability status score (EDSS) 1.5-5.5, and no immunomodulatory therapy at the time of the study. Treatment-free period will be at least 4 weeks for IV Methylprednisolone, Interferon-beta, Glatiramer acetate, Fingolimod, Tecfidera and Natalizumab. Patients previously treated with immunosuppressive therapies, including Azathioprine, Methotrexate, Mitoxantrone and Cyclophosphamide will not be enrolled in the study.  Exclusion Criteria:  Exclusion criteria will include concomitant infection, significant medical and psychiatric condition at the discretion of principal investigator. Pregnant women, and patients participating in other research trials will not be enrolled in this study.